Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665273 · ClinicalTrials.gov registry record · Phase 3
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
A Phase 3 study of Migraine, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02665273 is a Phase 3 study of Migraine that has completed, run by Montefiore Medical Center. The registered enrollment target is 28 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02665273, a Phase 3 study of Migraine, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.
Conditions Studied
Interventions
- DRUG Bupivacaine
- PROCEDURE Greater occipital nerve block
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665273
The ClinicalTrials.gov registry entry for NCT02665273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (92% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02665273 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02665273 about?
NCT02665273 is a clinical study titled "Greater Occipital Nerve Block With Bupivacaine for Acute Migraine". This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.
What is the current status of trial NCT02665273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2015-07-01. Estimated completion is 2018-01.
What conditions does trial NCT02665273 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02665273?
The interventions under investigation include: Bupivacaine (DRUG), Greater occipital nerve block (PROCEDURE).
Who is sponsoring clinical trial NCT02665273?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665273 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.